SCHEMBL1772244

SCHEMBL1772244

COC[C@H]1O[C@H](OC)[C@@H](OCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 5/20 0.67
SSTR1 P30872 4/20 0.67
SSTR2 P30874 4/20 0.67
SSTR4 P31391 4/20 0.67
SSTR3 P32745 4/20 0.67
BCHE P06276 1/20 0.57
PTPN1 P18031 5/20 0.47
PTPN2 P17706 3/20 0.47
GJB2 P29033 1/20 0.44
NT5E P21589 1/20 0.44
CDC25B P30305 2/20 0.44
ADRB2 P07550 1/20 0.43
TACR1 P25103 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3467445 1.00 SSTR5 (0.67) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL6879922 0.99 SSTR5 (0.65) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL6879920 0.99 SSTR5 (0.65) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL8152898 0.94 SSTR5 (0.60) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL8152902 0.94 SSTR5 (0.60) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL6383598 0.94 SSTR5 (0.64) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL6893382 0.92 SSTR5 (0.59) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL24122546 0.90 SSTR1 (0.72) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL6298172 0.90 SSTR1 (0.72) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL7148930 0.90 SSTR1 (0.72) SSTR5SSTR1SSTR2SSTR4SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130164387-A9 NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-06-27 US disclosed
US-20120269903-A1 NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-10-25 US disclosed
US-20110112044-A1 NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130164387-A9 NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY MAN2A1, MANBA, MAN2B1 SSTR5 3215/4885SSTR1 4137/4885SSTR2 3782/4885
US-20110112044-A1 NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES M6PR, BMP6, DCPS SSTR5 1473/4885SSTR1 1791/4885SSTR2 2335/4885
US-20120269903-A1 NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY MAN2A1, MANBA, MAN2B1 SSTR5 3215/4885SSTR1 4137/4885SSTR2 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.